Tritoqualine

• Description :

  Tritoqualine is a histidine decarboxylase inhibitor, that inhibits the release of histidine[1][2].

• Product Name Alternative :

  Inhibostamin; Hypostamine

• UNSPSC :

  12352005

• Hazard Statement :

  H315-H319-H320

• Target :

  Amino Acid Decarboxylase

• Type :

  Reference compound

• Related Pathways :

  Neuronal Signaling

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/Tritoqualine.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C1OC(C2N(C)CCC3=C2C(OC)=C(OCO4)C4=C3)C5=C1C(N)=C(OCC)C(OCC)=C5OCC

• Molecular Formula :

  C26H32N2O8

• Molecular Weight :

  500.54

• Precautions :

  P264-P280-P302+P352-P305+P351+P338-P362

• References & Citations :

  [1]Ishii K, et al. Therapeutic effect of histidine decarboxylase inhibitor on chronic active hepatitis. Gastroenterol Jpn. 1978;13 (2) :105-10.|[2]Yuasa S, et al. Suppressive effect of tritoqualine on lipid peroxidation and enzyme leakage induced by carbon tetrachloride in rat hepatocytes. Jpn J Pharmacol. 1986 Jun;41 (2) :205-10.|[3]Umezu K, et al. Inhibitory effect of tritoqualine (TRQ) on histamine release from mast cells. Jpn J Pharmacol. 1985 Jun;38 (2) :153-60.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [14504-73-5]